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The World Health Organisation (WHO) recommendations
for tuberculosis (TB) control focus on curing patients
presenting with their first episode of TB, with the aim of
interrupting TB transmission. In countries with a high TB
incidence, recurrent TB accounts for a significant
proportion of all cases,1,2 and HIV infection is a strong risk
factor for recurrent TB3-6 along with post-TB scarring,
cavities, drug regimen used to treat the initial episode of TB
and a low CD4 count.4-8 In settings of lower TB incidence,
recurrent TB occurs more commonly among HIV-infected
patients, though the absolute difference in rates is small.9
Recurrent TB may result from either recrudescence of
disease with the original infecting organism, or reinfection
with a new Mycobacterium tuberculosis strain.6,10
Reinfection, with rapid progression to disease, has been
shown to be an important cause of recurrence among HIV-
infected individuals in settings with high rates of TB
transmission.6
Current international guidelines recommend TB preventive
therapy (PT) for HIV-infected individuals who have never
had TB previously (primary TB PT).11 However, there is
increasing evidence of the efficacy of secondary PT for HIV-
infected individuals.12,13
The objective of our study was to determine the efficacy of
secondary isoniazid PT (IPT) by comparing the TB incidence
rates between two cohorts of HIV-infected goldminers in
South Africa with a history of previous TB who had or had
not received isoniazid PT.
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Objective. To determine the efficacy of secondary preventive therapy against tuberculosis (TB) among goldminers
working in South Africa.
Design. An observational study.
Methods. The incidence of recurrent TB was compared between two cohorts of HIV-infected miners: one cohort had
received secondary preventive therapy with isoniazid and the other had not. 
Setting. Health service providing comprehensive care for goldminers. 
Participants. 338 men received secondary preventive therapy and 221 did not.
Main outcome measure. Incidence of recurrent TB.
Results. The overall incidence of recurrent TB was reduced by 55% among men who received isoniazid preventive therapy
(IPT) compared to those who did not (incidence rates 8.6 and 19.1 per 100 person-years respectively, incidence rate ratio
0.45; 95% CI 0.26 – 0.78). The efficacy of isoniazid preventive therapy was unchanged after controlling for CD4 count
and age. The number of person-years of isoniazid preventive therapy required to prevent one case of recurrent TB among
individuals with a CD4 count < 200/µl and ≥ 200/µl was 5 and 19, respectively. 
Conclusion. Secondary preventive therapy reduces TB recurrence: the absolute impact appears to be greatest among
individuals with low CD4 counts. International TB preventive therapy guidelines for HIV-infected individuals need to be
expanded to include recommendations for secondary preventive therapy in settings where TB prevalence is high. 
Reprinted from AIDS (England), vol. 12, issue 14, pp.
2063-2070 (26 September 2003), with permission.
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STUDY POPULATION AND SITE
The study was conducted at a single goldmining company
in the Free State province of South Africa. The mine
hospital is the sole source of tertiary care for mine
employees and manages the TB control programme. Clinics
situated at most of the surrounding mine shafts provide
primary health care to miners and dispense TB treatment
and IPT. 
TB CONTROL PROGRAMME
The TB control programme includes directly observed
rifampicin-based short-course chemotherapy regimens,
use of combination tablets and active case detection using
a miniature radiograph screening programme. Treatment
regimens are in line with those recommended by the
national TB control programme: four drugs are used for
first episodes of TB, and regimens for drug-resistant cases
are modified to ensure treatment with two or more drugs
to which the isolate is sensitive. 
Miners with suspected TB are investigated according to a
standard protocol. Three sputum specimens are collected
over 2 days.  Smears are made from concentrated sputum
and stained with auramine for fluorescence microscopy.
Positive smears are confirmed with Ziehl-Neelsen staining.
Following decontamination with 4% sodium hydroxide,
sputum is inoculated onto Lowenstein-Jensen (L J) slopes
and incubated for up to 8 weeks. An initial identification
step for M. tuberculosis is carried out on L J slopes with
more than five colonies, using a colorimetric ribosomal
RNA hybridisation test (Accuprobe‚ M. tuberculosis complex
probe kit, Gen-Probe, San Diego, CA).  Positive cultures are
sent to the National Health Laboratory for drug
susceptibility testing of M. tuberculosis strains.
COHORT SELECTION
In this study we included miners with HIV infection and a
history of previous TB with documented successful
completion of TB treatment. Men who failed therapy for
the previous TB episode or had an unknown treatment
outcome were excluded from the study, as were men
treated for non-tuberculous mycobacterial disease.
Participants receiving IPT (300 mg/d) were derived from a
cohort of HIV-infected men receiving isoniazid and co-
trimoxazole indefinitely as part of a clinical trial. The
control cohort comprised men attending a routine HIV
clinic who did not receive IPT because of a history of
previous TB, an exclusion criterion in accordance with
current international and local guidelines. Men in the
control cohort received co-trimoxazole prophylaxis if their
CD4+ T cell-lymphocyte (CD4) count was below 250/µl if
symptomatic or 200/µl regardless of symptoms. The
incidence of TB recurrence in the two cohorts was
compared using a database listing all episodes of TB among
company employees since 1979. 
TIME AT RISK
At the time of recruitment to their respective cohorts, men
had blood taken for a CD4 count and were screened for TB
using symptoms, chest radiography and sputum smears
and cultures. In order to minimise the risk of including a
case of TB diagnosed at the time of screening as a study
case, the date of entry into this study was defined as three
months after the date of TB screening. Men receiving TB
treatment at the time of recruitment, or who were
diagnosed with TB at the time of screening, entered time at
risk after completing TB treatment. Time at risk was
censored at the time of first TB episode during the study,
death, loss to follow up or end of study (31 December 2000
for the IPT cohort and 31 July 2001 for the control cohort).
CASE DEFINITIONS
Recurrent TB was defined as definite if there were
compatible clinical features and sputum or tissue culture
was positive for M. tuberculosis; probable if there were
compatible clinical features and two sputum smears were
positive for acid-fast bacilli, or sputum or tissue culture
was positive for mycobacteria that were not further
speciated, or histological examination was positive (acid-
fast bacilli present or granulomatous disease); and possible
if there were compatible clinical features and a response to
treatment with anti-tuberculosis drugs. 
GRADING OF SILICOSIS AND POST-TREATMENT
SCARRING
The standard-sized chest radiographs of study participants,
taken at the time of recruitment to their respective cohorts,
were assessed for the presence and grade of silicosis using
a modified International Labour Organisation (ILO) scoring
system. For the purposes of this study silicosis was
categorised as none (0/0 or 0/1) or definite (ILO category
1/0 and above). The radiological extent of post-treatment
scarring was determined by dividing the lung on each side
into three equal zones and allocating a score according to
the total number of zones involved. The presence or
absence of cavities was also noted.
DATA ANALYSIS
Data were analysed with STATA 6.0 software (STATA
Corporation, Texas, USA). Differences between categorical
variables were investigated using the chi-square test or
Fisher’s exact test where appropriate. The differences in
length of follow-up between the two groups were assessed
METHODS
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using the Wilcoxon rank-sum test. Poisson regression was
used to calculate univariate and adjusted TB incidence and
mortality rate ratios for different variables. Overall
significance, tests for trends for ordinal variables with more
than two categories and tests for effect modification were
determined using the likelihood ratio test.
ETHICAL APPROVAL
Ethical approval for the clinical trial from which the IPT
cohort was drawn was obtained from the Anglogold Health
Services and UNAIDS ethical review boards; all participants
gave informed consent. The evaluation of the routine
health service clinic from which the control cohort was
drawn was given ethical approval by the ethics committees
of Anglogold Health Service and London School of Hygiene
and Tropical Medicine.
All study participants were HIV-infected black male miners;
338 men who received IPT (IPT cohort) were compared with
221 who did not (control cohort). The characteristics of the
two cohorts are presented in Table I. The two cohorts were
similar with respect to age, CD4 count, number of previous
TB episodes, silicosis grade, presence of cavitation and
extent of post-treatment scarring. The control cohort had
their preceding episode of TB significantly longer before
study entry than did the IPT cohort, and had a shorter
duration of follow-up within the study (median 0.41 v. 0.91
years). Recruitment to the IPT cohort began and ended a
year earlier than recruitment to the control cohort.
A log of all treatment dispensed to the primary health care
clinic and collected by the study participants on a monthly
basis was kept. Of men in the IPT cohort 76% (256/338)
collected at least 80% of the isoniazid dispensed; 19/28
(68%) of the TB cases from the IPT cohort collected at least
80% of their prescribed isoniazid. IPT was interrupted, and
then restarted, in 4 patients due to skin rash (2), abdominal
pain (1) and nausea (1). IPT was stopped and not restarted
in a further 3 patients, all due to skin rash. There were no
episodes of hepatitis or peripheral neuropathy.
Fifty-one cases of TB were diagnosed during the study
period, 28 (8.3%) among the IPT cohort and 23 (10.4%)
among the control cohort. The recurrent TB cases in the
two groups were similar with respect to the proportion
classified as definite, site of disease and CD4 count at
baseline (Table II). There was no significant difference in the
prevalence of isoniazid resistance between the IPT and
control cohorts (20% [2/10] and 23% [3/13], respectively, 
p = 1.0). 
Results of incidence rates (IR) of recurrent TB, unadjusted
incidence rate ratios (IRR) and 95% confidence intervals
(CI) are presented in Tables III and IV. There was a
significantly lower incidence of TB among the IPT cohort
compared with the control cohort (IRR 0.45; 95% CI 0.26 -
0.78). There was no difference in efficacy of IPT when
adjusted for age, silicosis, extent of post-treatment scarring
or presence of cavitation, CD4 count and time since
RESULTS 
IPT Control
N % N % p-value
Total 338 221
Time at risk (yrs)
Median  (IQR) 0.91 (0.60, 1.33) 0.41 (0.19, 0.84) < 0.001
Age group (yrs)
< 30 17 5 11 5 0.5
30 - 39 154 46 86 39
40 - 49 139 41 104 47
50+ 28 8 20 9
CD4 group (/µl)*
< 200 114 34 65 33 0.2
200 - 499 181 54 95 49
500+ 42 12 35 18
Time since end of previous 
TB episode (mo.)
6 - 12 256 76 131 59 < 0.001
12 - 24 49 14 38 17
24+ 33 10 52 24
Calendar year of entry
1998 59 17 0 0 < 0.001
1999 - 2000 279 83 140 63
2001 0 0 81 37
Number of previous TB episodes
1 273 81 173 78 0.5
> 1 65 19 48 22
Silicosis
Absent 307 91 206 93 0.3
Present 31 9 15 7
Cavitation
Absent 265 78 165 75 0.3
Present 73 22 56 25
Number of zones
0 57 17 42 19 0.7
1 - 2 177 52 117 53
3+ 104 31 62 28
*1 and 26 results missing for IPT and control cohorts, respectively. 
IPT = isoniazid preventive; therapy; IQR = inter-quartile range.
TABLE I. SUMMARY OF DEMOGRAPHIC VARIABLES, 
BY COHORT
IPT Control
Factor N % N % p-value
Total 28 23
Case definition
Definite 17 61 18 78 0.2
Probable 11 39 5 22
Classification
PTB 22 79 18 78 0.7
ETB 4 14 2 8
PTB + ETB 2 7 3 13
CD4 group (/µl)*
< 200 12 43 10 50 0.5
≥ 200 16 57 10 50
*CD4 group at baseline. CD4 count missing for 3 individuals from the control cohort.
TABLE II. SUMMARY OF TB EVENTS, BY COHORT
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completion of treatment for previous TB episode (adjusted
IRR = 0.45, 95% CI 0.26 - 0.79). The effect of IPT on TB
incidence remained significant when the analysis was
restricted to TB cases defined as probable or definite (Table
III). Likewise, the effect of IPT remained highly significant if
the analysis was restricted to those in whom the previous
TB episode had been culture positive for M. tuberculosis
(IRR 0.19; 95% CI 0.09 - 0.42) (Table IV). 
Among men with only one previous episode of TB, the
incidence of recurrent TB in the IPT cohort was significantly
lower than in the control cohort (Table III). Among men
with more than one previous episode of TB, recurrences
occurred more often in those on IPT, though the difference
was not statistically significant (Table III). The interaction
between the number of previous TB episodes and the
efficacy of IPT was significant overall (Pinteraction = 0.03),
when the analysis was restricted to those cases classified as
probable or definite (Pinteraction = 0.02) (Table III) and when
the preceding TB episode was culture positive for M.
tuberculosis (Pinteraction = 0.001) (Table IV). The effect of IPT
was strongest in men with only one previous episode of TB
that was culture positive for M. tuberculosis, among whom
there was an 89% reduction in incidence of recurrent TB
(IRR 0.11; 95% CI 0.04 – 0.27). 
The effect of IPT was not significantly modified by time
since completion of previous TB treatment (Pinteraction =
0.86) or by CD4 category (Pinteraction = 0.55) (Table III).
However, the incidence of recurrent TB increased with
N Events*/pyrs IR IRR (95% CI)
All
Overall IPT 338 28/324.3 8.6 0.45 (0.26, 0.78)
Control 221 23/120.3 19.1 1
Previous episodes of TB Pi =0.03†
1 episode IPT 273 19/268.3 7.1 0.33 (0.18, 0.61)
Control 173 21/97.2 21.6 1
> 1 episode IPT 65 9/56.0 16.1 1.85 (0.40, 8.58)
Control 48 2/23.1 8.7 1
CD4 category (/µl) Pi = 0.55†
< 200 IPT 114 12/87.8 13.7 0.40 (0.17, 0.92)
Control 65 10/29.1 34.3 1
≥ 200 IPT 223 16/234.8 6.8 0.57 (0.26, 1.25)
Control 135 10/83.0 12.0 1
Time since previous TB episode Pi =0.86†
< 12 mo. IPT 202 13/183.5 7.1 0.52 (0.22, 1.27)
Control 111 8/59.3 13.5 1
12 - 24 mo. IPT 83 10/87.1 11.5 0.37 (0.15, 0.94)
Control 50 8/26.0 30.8 1
>24 mo. IPT 53 5/53.7 9.3 0.47 (0.15, 1.47)
Control 60 7/35.1 19.9 1
Probable/definite‡
Overall IPT 338 17/324.3 5.2 0.35 (0.18, 0.68)
Control 221 18/120.3 15.0 1
Previous episodes of TB Pi = 0.02†
1 episode IPT 273 11/268.3 4.1 0.23 (0.11, 0.50)
Control 173 17/97.2 17.5 1
>1 episode IPT 65 6/56.0 10.7 2.47 (0.30, 20.5)
Control 48 1/23.1 4.3
IR = incidence rate per 100 person-years (pyrs); IRR = incidence rate ratio; CI = confidence interval; IPT = isoniazid preventive therapy. *Number of TB recurrences. †P-value for the interaction
between variable of interest and cohort group. ‡See text for case definitions.
TABLE III. UNADJUSTED INCIDENCE RATES OF RECURRENT TB AND INCIDENCE RATE RATIOS BY NUMBER OF
PREVIOUS TB EPISODES, CD4 GROUP, TIME SINCE PREVIOUS TB EPISODE AND TB CASE DEFINITION
N Events*/pyrs IR IRR (95% CI)
All
Overall IPT 186 10/176.4 5.7 0.19 (0.09, 0.42)
Control 119 17/58.1 29.3 1
Previous episodes of TB Pi = 0.01†
1 episode IPT 155 6/151.1 4.0 0.11 (0.4, 0.27)
Control 94 17/46.4 36.6 1
> 1 episode IPT 31 14/25.3 15.8 -
Control 25 0/11.7 0
IR = incidence rate per 100 person years (pyrs); IRR = incidence rate ratio; CI = confidence interval; IPT = isoniazid preventive therapy. †Number of TB recurrences. *p-value for interaction of the
number of previous TB episodes.
TABLE IV. UNADJUSTED INCIDENCE RATES OF RECURRENT TB AND INCIDENCE RATE RATIOS RESTRICTED TO
INDIVIDUALS WHOSE PREVIOUS TB EPISODE WAS CULTURE POSITIVE FOR M. TUBERCULOSIS
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decreasing CD4 count (CD4 count ≥ 500/µl: 6.9/100
person-years (pyrs); CD4 count 200 – 499/µl: 8.6/100 pyrs;
< 200/µl: 18.8/100 pyrs; Ptrend = 0.008) and hence the
number needed to treat to prevent a case of recurrent TB
was substantially lower for individuals with lower CD4
counts. (The number of pyrs on IPT required to prevent one
case of recurrent TB was 10 pyrs overall, 5 pyrs for CD4
count < 200/µl and 19 pyrs for CD4 count ≥ 200/µl.)
Overall mortality was not significantly lower among the IPT
cohort compared with the control cohort (mortality rate
ratio 0.7; 95% CI 0.39 - 1.24) (Table V). In order to control
for any possible effect of co-trimoxazole on mortality, the
analysis was restricted to those men with a CD4 count of
200/µl or below who were taking co-trimoxazole, but this
did not affect the result (mortality rate ratio 0.73; 95% CI
0.39 - 1.38). 
The concept of TB PT was developed in the pre-HIV era,
based on the idea that treatment of asymptomatic latent or
recently acquired TB infection would reduce the risk of
developing active TB disease.14 In industrialised countries,
the contribution of exogenous reinfection to active disease
was declining in the mid-20th century,15 and PT was
thought to have no effect among those who had been
previously treated for TB16 and secondary PT was therefore
not recommended. The clinical trials that demonstrated the
efficacy of TB PT among HIV-infected individuals were
based on this same principle, and hence only included
individuals who had no history of previous TB. However,
with the development of molecular ‘fingerprinting’
techniques, it has become clear that recurrent TB may
occur either as a result of recrudescence of disease from
the original infecting organism (relapse) or due to
reinfection with a new strain of TB, particularly in settings
with a high rate of TB transmission.6,10
In this study, in a setting where the prevalence (and hence
also the risk of transmission) of TB is high, secondary IPT
was associated with a 55% reduction in the incidence of
recurrent TB among HIV-infected individuals. The results
are consistent with small prospective randomised trials of
secondary IPT from Haiti12 and Abidjan,13 and a study from
the Democratic Republic of Congo that demonstrated a
reduction in TB recurrence among HIV-infected individuals
in whom treatment was extended by 6 months with twice-
weekly isoniazid and rifampicin.17
The effectiveness of secondary PT is likely to be limited to
communities with high rates of TB transmission, such as
the South African goldmining industry, where there are
high rates of TB recurrence following documented cure,
particularly among HIV-infected individuals.4,6 DNA
fingerprinting data suggest similar rates of relapse
between HIV-infected and uninfected individuals, but
higher rates of reinfection with rapid progression to TB
disease among HIV-infected individuals.6 In this setting,
secondary PT may prevent acquisition of new infection or
treat recently acquired infection that may have occurred
following completion of treatment of the previous TB
episode.
Our study suggests that the effectiveness of secondary IPT
may be limited to HIV-infected individuals with only one
previous episode of TB. This may be because individuals
who have had more than one recurrence of TB are more
likely to have drug-resistant TB than those individuals
presenting with their first recurrence;18 the number of
individuals in this study with isoniazid-resistant TB was too
small to provide data supporting this hypothesis. Limiting
secondary PT to individuals who have only had one
previous episode of TB seems rational but requires
additional studies to confirm a lack of benefit in those
individuals with more than one previous TB episode.
Current WHO recommendations regarding TB preventive
therapy for HIV-infected individuals in resource-poor
settings have not been widely implemented.19 In sub-
Saharan Africa the majority of HIV-infected individuals are
unaware of their HIV status19 and many discover their
status only when an opportunistic infection, often TB, is
diagnosed, at which point it is too late for primary PT.
Furthermore, owing to limited eligibility criteria and
logistical difficulties of excluding active disease prior to
commencing PT there is a high attrition of patients during
the screening process.20 Consequently, the number of
patients who start primary PT compared with the number
Events*/pyrs MR MRR (95% CI) p-value
All individuals IPT 33/339.8 10.0 0.70 (0.39, 1.24) 0.22
Control 18/129.3 13.9 1
CD4 < 200/µl, on  IPT 30/93.1 33.3 0.73 (0.39, 1.38) 0.33
co-trimoxazole† Control 14/31.8 44.1 1
MR = mortality rate per 100 person years (pyrs); MRR = mortality rate ratio; CI = confidence interval; IPT = isoniazid preventive therapy.
*Number of deaths. †114 and 60 individuals from the IPT and control cohorts, respectively.
TABLE V. MORTALITY RATES AND RATE RATIOS BY COHORT
DISCUSSION
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screened is small. Secondary TB PT may be easier to
implement than primary PT. HIV testing should have been
offered at the time of TB diagnosis, a tuberculin skin test
(TST) and chest radiograph are not required and exclusion
of active TB at the end of treatment, by sputum smear
examination, is done routinely according to WHO TB
control programme guidelines. For these reasons it seems
logical to offer secondary PT to HIV-infected individuals in
settings of high TB prevalence where primary TB PT is being
offered.
In this study, the risk of recurrent TB increased significantly
with declining CD4 count, but the relative effect of IPT was
not significantly modified by CD4 count. Hence fewer
patients with advanced HIV disease would need to be
treated to prevent a case of TB compared to patients with
less advanced HIV disease. It may be more cost-effective to
target IPT to those with advanced HIV disease, based on
CD4 count or clinical staging. Of note, absolute numbers
needed to treat depend on TB incidence and hence where
TB incidence is lower, the numbers needed to treat will be
higher.
In other studies12,17 the effectiveness of secondary PT was
evaluated in the immediate post-TB treatment period.13 Our
study demonstrated effectiveness of secondary IPT
regardless of the interval between the previous TB episode
and commencing IPT. We therefore propose no restriction
by time since previous episode for offering secondary PT to
HIV-infected individuals.
Although secondary IPT significantly reduced the incidence
of TB recurrence in this study, the rate of recurrence in the
IPT cohort remained unacceptably high (8.6 per 100
person-years) and mortality was not significantly reduced.
In resource-poor settings secondary IPT may be a safe and,
at less than $10 per person per year, affordable way to
reduce morbidity among HIV-infected individuals with a
history of previous TB. Antiretroviral therapy (ART) is likely
to have a greater effect in reducing morbidity and mortality
from TB and AIDS-defining conditions in this group of
patients.21,22 However, TB incidence remains high among
individuals on ART with low CD4 counts living in
communities with endemic TB,22 and thus TB preventive
therapy will remain an important intervention for
individuals receiving ART in these settings.
In this study, we were able to include a relatively large
number of individuals with a large number of events. Since
this was not a randomised controlled trial, there could have
been differences between the two cohorts that we were not
able to control for. However, we had access to detailed data
on potential confounding factors, and the two cohorts had
similar baseline characteristics. Although the two cohorts
differed in terms of time since last TB episode, there was no
difference in efficacy of IPT when adjusted for time since
last TB episode. The risk of recurrent TB in the IPT cohort
may have been greater because of the longer duration of
follow-up and hence increased chance of disease
progression. If so, we may have underestimated the
efficacy of IPT.
Secondary IPT was administered indefinitely in this study,
which contrasts with current international guidelines of 
6 - 9 months of isoniazid for primary PT11,23 and other
studies of secondary PT.12,13 Further work is needed to
determine the optimum duration of both primary and
secondary TB PT in settings with high rates of TB
transmission, and to establish how best to target PT.
There is a growing body of evidence of the efficacy of
secondary TB PT for HIV-infected individuals in
communities with a high incidence of TB. HIV-infected
individuals may benefit from secondary PT, and
international recommendations need revision to take this
into account. 
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Commentary by G J Churchyard and 
A D Grant
South Africa is classified by the World Health Organisation as one of the 22 high TB burden countries world-wide.1
Approximately 2 million South Africans are co-infected with TB and HIV, and the estimated incidence of all forms of TB
was 509 per 100 000 population for 2002, with 60% of adult cases being HIV-infected.1
As in other countries with endemic TB, recurrent disease accounts for a significant proportion of all TB in South Africa.
HIV infection increases the risk of recurrence following successful treatment of TB.2 Risk factors for recurrence of HIV-
associated TB are initial treatment regimens with less than 6 months of rifampicin,2 post-TB scarring, cavities, and a low
CD4 count.
The importance of new infection as a cause of recurrent TB has been clearly shown in a prospective strain-typing study
among TB patients in a South African goldmine.3 HIV-infected miners had recurrent TB disease due to a new strain of TB
(reinfection) at 18.7 times the rate in HIV-uninfected miners, but there was no increase in their risk of recurrent disease
due to the original strain (relapse).  In settings of lower TB incidence, recurrent TB still occurs more frequently among
HIV-infected patients, although the absolute difference is smaller. These observations suggest that that there is little to
gain from intensifying the treatment regimens currently used in South Africa, but that consideration should be given to
secondary TB preventive therapy in settings of high TB transmission. The article by Churchyard et al.4 reproduced in this
journal contributes to the body of evidence supporting the use of secondary TB preventive therapy among HIV-infected
individuals. Although the South African HIV Clinicians Society guidelines recommend TB preventive therapy for HIV-
infected individuals who have had an episode of TB more than 2 years previously, the Department of Health’s TB
preventive therapy guidelines do not advocate the use of secondary TB preventive therapy.  Further research is needed
to establish how to use secondary TB preventive therapy most effectively among HIV-infected people, and to determine
whether secondary TB preventive therapy has a role to reduce TB recurrence among individuals receiving antiretroviral
therapy. 
REFERENCES
1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163(9): 1009-1021.
2. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an
analytical review. Clin Infect Dis 2003; 37: 101-112.
3. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South
African mineworkers. Lancet 2001; 358: 1687-1693.
4. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected southern Africans: time to change policy? AIDS 2003;
14: 2063-2070.
